CoChat

A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

Malignant mesothelioma is an aggressive and lethal pleural cancer that overexpresses transforming growth factor beta (TGFbeta). We investigated the efficacy of a novel small-molecule TGFbeta type I receptor (ALK5) kinase inhibitor, SM16, in the AB12 syngeneic model of malignant mesothelioma. SM16 inhibited TGFbeta signaling seen as decreased phosphorylated Smad2/3 levels in cultured AB12 cells (IC(50), approximately 200 nmol/L). SM16 penetrated tumor cells in vivo, suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single i.p. bolus of 20 mg/kg SM16. The growth of established AB12 tumors was significantly inhibited by 5 mg/kg/d SM16 (P < 0.001) delivered via s.c. miniosmotic pumps over 28 days. The efficacy of SM16 was a result of a CD8+ antitumor response because (a) the antitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8+ T cells isolated from spleens of mice treated with SM16 showed strong antitumor cytolytic effects whereas CD8+ T cells isolated from spleens of tumor-bearing mice treated with control vehicle showed minimal activity. Treatment of mice bearing large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence from 80% to <20% (P < 0.05). SM16 was also highly effective in blocking and regressing tumors when given p.o. at doses of 0.45 or 0.65 g/kg in mouse chow. Thus, SM16 shows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated mechanism and can significantly prevent tumor recurrence after resection of bulky AB12 malignant mesothelioma tumors. These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-2389

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM. Transforming the TFGβ pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discov Devel 2004; 7: 437–45.

Cited by

See all 125

Metadata

Authors
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., & Ling, L. E.
Affiliations
  • University of Pennsylvania (US)
  • Biogen (United States) (US)
  • 1Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania and
Venue
Cancer Research
Published
2007-03-01
Volume
67
Issue
5
Pages
2351-2359
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2122411707
Cited by
113
References
61
Citations by year
2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 10 · 2013: 8 · 2012: 17
FWCI
4.33
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA066726)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
malignant mesothelioma, TGF-beta type I receptor, TGF-beta signaling, Smad2/3 phosphorylation, tumor recurrence after resection, CD8+ T cells, antitumor immunity, oral drug delivery, small-molecule kinase inhibitors
MeSH terms
Receptor, Transforming Growth Factor-beta Type I, Animals, Drug Evaluation, Preclinical, Female, Humans, Immunity, Cellular, Mesothelioma, Mice, Inbred BALB C, Neoplasm Recurrence, Local, Neoplasm Transplantation, Tumor Cells, Cultured, Mice, SCID, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Disease-Free Survival, Activin Receptors, Type I, Protein Kinase Inhibitors, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-2389
The paper
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., & Ling, L. E. (2007). A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-2389

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.